JP2006523181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006523181A5 JP2006523181A5 JP2004555869A JP2004555869A JP2006523181A5 JP 2006523181 A5 JP2006523181 A5 JP 2006523181A5 JP 2004555869 A JP2004555869 A JP 2004555869A JP 2004555869 A JP2004555869 A JP 2004555869A JP 2006523181 A5 JP2006523181 A5 JP 2006523181A5
- Authority
- JP
- Japan
- Prior art keywords
- cys
- xaa1
- amino acid
- lys leu
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- PINHPJWGVBKQII-SRVKXCTJSA-N Lys-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N PINHPJWGVBKQII-SRVKXCTJSA-N 0.000 claims 10
- DKJWUIYLMLUBDX-XPUUQOCRSA-N Gly-Val-Cys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)O DKJWUIYLMLUBDX-XPUUQOCRSA-N 0.000 claims 9
- 108010004073 cysteinylcysteine Proteins 0.000 claims 9
- 108010059898 glycyl-tyrosyl-lysine Proteins 0.000 claims 9
- YKKHFPGOZXQAGK-QWRGUYRKSA-N Cys-Gly-Tyr Chemical compound SC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YKKHFPGOZXQAGK-QWRGUYRKSA-N 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical group OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 5
- 150000001408 amides Chemical class 0.000 claims 5
- 150000001413 amino acids Chemical group 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- ODHCTXKNWHHXJC-GSVOUGTGSA-N 5-oxo-D-proline Chemical compound OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 208000000094 Chronic Pain Diseases 0.000 claims 3
- 150000008574 D-amino acids Chemical class 0.000 claims 3
- HBGKOLSGLYMWSW-DCAQKATOSA-N His-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)N)C(=O)N[C@@H](CS)C(=O)O HBGKOLSGLYMWSW-DCAQKATOSA-N 0.000 claims 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 claims 3
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 208000005298 acute pain Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 3
- 229960002591 hydroxyproline Drugs 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 230000001537 neural effect Effects 0.000 claims 3
- 208000014001 urinary system disease Diseases 0.000 claims 3
- QRXPIKKZQGWJMW-ZETCQYMHSA-N 4-O-methyl-L-dopa zwitterion Chemical compound COC1=CC=C(C[C@H](N)C(O)=O)C=C1O QRXPIKKZQGWJMW-ZETCQYMHSA-N 0.000 claims 2
- OOWSBIOUKIUWLO-RCOVLWMOSA-N Asn-Gly-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O OOWSBIOUKIUWLO-RCOVLWMOSA-N 0.000 claims 2
- ZJBWJHQDOIMVLM-WHFBIAKZSA-N Cys-Cys-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O ZJBWJHQDOIMVLM-WHFBIAKZSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims 1
- 229930195710 D‐cysteine Natural products 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- FMXFHNSFABRVFZ-BZSNNMDCSA-N Tyr-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FMXFHNSFABRVFZ-BZSNNMDCSA-N 0.000 claims 1
- 208000012931 Urologic disease Diseases 0.000 claims 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 108050003126 conotoxin Proteins 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 229940043131 pyroglutamate Drugs 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43030602P | 2002-12-02 | 2002-12-02 | |
| PCT/AU2003/001605 WO2004050690A1 (en) | 2002-12-02 | 2003-12-02 | NOVEL χ-CONOTOXIN PEPTIDES (-I) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006523181A JP2006523181A (ja) | 2006-10-12 |
| JP2006523181A5 true JP2006523181A5 (enExample) | 2006-11-24 |
| JP4565087B2 JP4565087B2 (ja) | 2010-10-20 |
Family
ID=32469446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004555869A Expired - Fee Related JP4565087B2 (ja) | 2002-12-02 | 2003-12-02 | 新規なχ−コノトキシン・ペプチド（−Ｉ） |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7851444B2 (enExample) |
| EP (1) | EP1572725B1 (enExample) |
| JP (1) | JP4565087B2 (enExample) |
| AT (1) | ATE547424T1 (enExample) |
| AU (1) | AU2003302609B9 (enExample) |
| CA (1) | CA2508129C (enExample) |
| CY (1) | CY1112839T1 (enExample) |
| DK (1) | DK1572725T3 (enExample) |
| ES (1) | ES2383358T3 (enExample) |
| NZ (1) | NZ540518A (enExample) |
| PT (1) | PT1572725E (enExample) |
| SI (1) | SI1572725T1 (enExample) |
| WO (1) | WO2004050690A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP627498A0 (en) * | 1998-10-02 | 1998-10-22 | University Of Queensland, The | Novel peptides - i |
| WO2004050688A1 (en) * | 2002-12-02 | 2004-06-17 | Xenome Ltd | NOVEL χ-CONOTOXIN PEPTIDES (-II) |
| US8062623B2 (en) * | 2004-10-15 | 2011-11-22 | Velocys | Stable, catalyzed, high temperature combustion in microchannel, integrated combustion reactors |
| US20070154360A1 (en) * | 2005-10-13 | 2007-07-05 | Velocys Inc. | Microchannel apparatus comprising a platinum aluminide layer and chemical processes using the apparatus |
| CN102752032B (zh) * | 2011-04-22 | 2015-04-22 | 艾利森电话股份有限公司 | 同频负载均衡方法及其设备 |
| CA2986704C (en) * | 2015-05-22 | 2022-03-01 | Clemson University Research Foundation | Conotoxin peptides for use in biofouling deterrence |
| CN119462881A (zh) * | 2024-12-20 | 2025-02-18 | 深圳肽盛生物科技有限公司 | μ型芋螺毒素肽及其药物组合物和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5051403A (en) | 1989-11-22 | 1991-09-24 | Neurex Corporation | Method of treating ischemia-related neuronal damage |
| ZA921292B (en) | 1991-02-25 | 1993-08-23 | Lilly Co Eli | Treatment of lower urinary tract disorders. |
| CA2151741C (en) * | 1991-12-30 | 2001-12-11 | Alan Justice | Methods of producing analgesia and enhancing opiate analgesia |
| PT789580E (pt) | 1994-11-03 | 2002-09-30 | Novartis Ag | Formulacoes de ciclosporina para administracao oral com composicao simples e alta biodisponibilidade e processo para a sua producao |
| WO1996040064A1 (en) | 1995-06-07 | 1996-12-19 | Nexstar Pharmaceuticals, Inc. | Liposomal cyclosporin formulations as agents for immunosuppression and multiple drug resistant indications |
| DK0835126T3 (da) | 1995-06-27 | 2003-07-14 | Elan Pharm Inc | Sammensætninger og formuleringer til fremstilling af analgesimidler og til hamning af fremadskridende neuropatiske amertelidelser |
| TR199801641T2 (xx) | 1996-02-22 | 1998-11-23 | Neurosearch A/S | Tropan t�revleri bunlar�n haz�rlanmas� ve kullan�m� |
| GB9614902D0 (en) | 1996-07-16 | 1996-09-04 | Rhodes John | Sustained release composition |
| CZ288739B6 (cs) | 1996-08-01 | 2001-08-15 | Galena, A. S. | Cyklosporin obsahující léčivé přípravky |
| JP2001505878A (ja) | 1996-11-18 | 2001-05-08 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション | 心臓血管剤としてのコノトキシンペプチドＩｍＩおよびＭＩＩの使用 |
| EP0981515B1 (en) | 1997-05-14 | 2003-08-27 | Neurosearch A/S | Piperidine derivatives as neurotransmitter re-uptake inhibitors |
| AUPP627498A0 (en) | 1998-10-02 | 1998-10-22 | University Of Queensland, The | Novel peptides - i |
| US6767896B1 (en) * | 1999-01-29 | 2004-07-27 | Cognetix, Inc. | Conotoxin peptides |
| WO2000044769A1 (en) * | 1999-01-29 | 2000-08-03 | University Of Utah Research Foundation | Conotoxin peptides |
| US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| WO2002060923A2 (en) * | 2001-01-29 | 2002-08-08 | Cognetix, Inc. | B-superfamily conotoxins |
| WO2002064740A2 (en) * | 2001-02-09 | 2002-08-22 | Cognetix, Inc. | Cone snail peptides |
| WO2004050688A1 (en) * | 2002-12-02 | 2004-06-17 | Xenome Ltd | NOVEL χ-CONOTOXIN PEPTIDES (-II) |
-
2003
- 2003-12-02 DK DK03812100.0T patent/DK1572725T3/da active
- 2003-12-02 WO PCT/AU2003/001605 patent/WO2004050690A1/en not_active Ceased
- 2003-12-02 NZ NZ540518A patent/NZ540518A/en not_active IP Right Cessation
- 2003-12-02 AT AT03812100T patent/ATE547424T1/de active
- 2003-12-02 PT PT03812100T patent/PT1572725E/pt unknown
- 2003-12-02 US US10/537,704 patent/US7851444B2/en not_active Expired - Fee Related
- 2003-12-02 AU AU2003302609A patent/AU2003302609B9/en not_active Ceased
- 2003-12-02 JP JP2004555869A patent/JP4565087B2/ja not_active Expired - Fee Related
- 2003-12-02 EP EP03812100A patent/EP1572725B1/en not_active Expired - Lifetime
- 2003-12-02 SI SI200332154T patent/SI1572725T1/sl unknown
- 2003-12-02 ES ES03812100T patent/ES2383358T3/es not_active Expired - Lifetime
- 2003-12-02 CA CA2508129A patent/CA2508129C/en not_active Expired - Fee Related
-
2012
- 2012-05-29 CY CY20121100484T patent/CY1112839T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018205186B2 (en) | Angiotensin in treating brain conditions | |
| NZ621196A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| WO2009034134A3 (en) | Use of natriuretic peptides for treating angioedema syndromes | |
| JP2012506442A5 (enExample) | ||
| CA2550085A1 (en) | Small peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders | |
| CA2545499A1 (en) | Antagonists of the bradykinin b1 receptor | |
| JP2006523181A5 (enExample) | ||
| JP2016520592A (ja) | マルファン症候群および関連障害の処置におけるアンジオテンシンペプチド | |
| CY1112839T1 (el) | Πεπτιδια χ-κωνοτοξινες που εχουν ενα αμινοτελικο πυρογλουταμικο οξυ | |
| US20110034557A1 (en) | Antimicrobial compositions and uses thereof | |
| CA2940751C (en) | Uses of an angiotensin (1-7) peptide for the delayed treatment of stroke | |
| JP2001524529A (ja) | トレオニン含有プロテグリン | |
| CN101808655B (zh) | 衍生自纤溶酶原激活物抑制剂-1的肽和其应用 | |
| RU2009103811A (ru) | Аналоги вазоактивного интестинального пептида | |
| EP2439209B1 (en) | Endokinin c/d-origin peptides | |
| ZA200603912B (en) | Antagonists of the Bradykinin B1 receptor | |
| MXPA06004462A (es) | Antagonistas del receptor b1 de bradiquinina | |
| WO2016010844A1 (en) | Methods and compositions for the treatment of stroke | |
| HK1145397B (en) | Peptides derived from plasminogen activator inhibitor-1 and uses thereof |